CN111542546A - 抗lag-3 抗体及其用途 - Google Patents

抗lag-3 抗体及其用途 Download PDF

Info

Publication number
CN111542546A
CN111542546A CN201980006640.4A CN201980006640A CN111542546A CN 111542546 A CN111542546 A CN 111542546A CN 201980006640 A CN201980006640 A CN 201980006640A CN 111542546 A CN111542546 A CN 111542546A
Authority
CN
China
Prior art keywords
seq
antibody
antigen
sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980006640.4A
Other languages
English (en)
Other versions
CN111542546B (zh
Inventor
薛彤彤
***
肖亮
郑云程
刘登念
陈思
胡彦
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Anyuan Pharmaceutical Technology Shanghai Co ltd
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anyuan Pharmaceutical Technology Shanghai Co ltd, Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Anyuan Pharmaceutical Technology Shanghai Co ltd
Publication of CN111542546A publication Critical patent/CN111542546A/zh
Application granted granted Critical
Publication of CN111542546B publication Critical patent/CN111542546B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及疾病治疗及免疫学领域，具体而言，本发明涉及抗LAG‑3的抗体或其抗原结合片段，编码它们的核酸分子，制备它们的方法。本发明的抗LAG‑3抗体或其抗原结合片段对LAG‑3具有高特异性和高亲和力，能够有效阻断LAG‑3与MHC II和/或FGL1的结合，抑制和/或阻断由LAG‑3结合MHC II和/或FGL1所介导的细胞内信号传导。因此，本发明进一步涉及包含所述抗体或其抗原结合片段的药物组合物，以及其在制备药物中的用途，所述药物用于提高免疫细胞活性、增强免疫应答，或者用于预防和/或***、感染或自身免疫性疾病。

Description

PCT国内申请，说明书已公开。

Claims (33)

  1. PCT国内申请，权利要求书已公开。
CN201980006640.4A 2018-01-18 2019-01-03 抗lag-3抗体及其用途 Active CN111542546B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018100507599 2018-01-18
CN201810050759 2018-01-18
PCT/CN2019/070303 WO2019141092A1 (zh) 2018-01-18 2019-01-03 抗lag-3抗体及其用途

Publications (2)

Publication Number Publication Date
CN111542546A true CN111542546A (zh) 2020-08-14
CN111542546B CN111542546B (zh) 2022-08-16

Family

ID=67300939

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980006640.4A Active CN111542546B (zh) 2018-01-18 2019-01-03 抗lag-3抗体及其用途

Country Status (3)

Country Link
US (1) US11655295B2 (zh)
CN (1) CN111542546B (zh)
WO (1) WO2019141092A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113789347A (zh) * 2021-09-23 2021-12-14 徐州医科大学 Fgl1/caix双靶点疫苗在治疗肾癌和肾癌肺转移中的应用
CN114480298A (zh) * 2022-04-14 2022-05-13 迈杰转化医学研究(苏州)有限公司 一株分泌抗tigit单克隆抗体的杂交瘤细胞株及其应用
CN114685658A (zh) * 2020-12-30 2022-07-01 百力司康生物医药(杭州)有限公司 Ox40的靶向抗体及其制备方法和应用
CN116514972A (zh) * 2020-12-10 2023-08-01 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021527082A (ja) * 2018-06-11 2021-10-11 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 新規な免疫チェックポイント阻害剤
KR20220070201A (ko) 2019-09-30 2022-05-30 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-pd-1 항체 및 이의 용도
CN111205371B (zh) * 2020-01-22 2022-03-29 北京吉尔麦迪生物医药科技有限公司 一种抗淋巴细胞激活基因3的抗体及应用
WO2022166987A1 (zh) * 2021-02-08 2022-08-11 迈威(上海)生物科技股份有限公司 结合lag-3的抗体及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176921A (zh) * 2008-08-11 2011-09-07 梅达雷克斯股份有限公司 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途
CN104411723A (zh) * 2012-07-02 2015-03-11 百时美施贵宝公司 结合淋巴细胞活化基因-3(lag-3)的抗体的优化及该抗体的用途
CN105793287A (zh) * 2013-09-20 2016-07-20 百时美施贵宝公司 抗lag-3抗体与抗pd-1抗体联合***
CN107001470A (zh) * 2014-08-19 2017-08-01 默沙东公司 抗‑lag3抗体和抗原结合片段
TW201726740A (zh) * 2015-11-18 2017-08-01 默沙東藥廠 Pd1及/或lag3結合劑
CN107001478A (zh) * 2014-10-14 2017-08-01 诺华股份有限公司 针对pd‑l1的抗体分子及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2913343T (pt) * 2005-12-20 2018-11-21 Sbi Biotech Co Ltd Anticorpo anti-ilt7
WO2017085035A1 (en) * 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176921A (zh) * 2008-08-11 2011-09-07 梅达雷克斯股份有限公司 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途
CN104411723A (zh) * 2012-07-02 2015-03-11 百时美施贵宝公司 结合淋巴细胞活化基因-3(lag-3)的抗体的优化及该抗体的用途
CN105793287A (zh) * 2013-09-20 2016-07-20 百时美施贵宝公司 抗lag-3抗体与抗pd-1抗体联合***
CN107001470A (zh) * 2014-08-19 2017-08-01 默沙东公司 抗‑lag3抗体和抗原结合片段
CN107001478A (zh) * 2014-10-14 2017-08-01 诺华股份有限公司 针对pd‑l1的抗体分子及其用途
TW201726740A (zh) * 2015-11-18 2017-08-01 默沙東藥廠 Pd1及/或lag3結合劑

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116514972A (zh) * 2020-12-10 2023-08-01 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN116514971A (zh) * 2020-12-10 2023-08-01 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN116514971B (zh) * 2020-12-10 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN116514972B (zh) * 2020-12-10 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN114685658A (zh) * 2020-12-30 2022-07-01 百力司康生物医药(杭州)有限公司 Ox40的靶向抗体及其制备方法和应用
CN113789347A (zh) * 2021-09-23 2021-12-14 徐州医科大学 Fgl1/caix双靶点疫苗在治疗肾癌和肾癌肺转移中的应用
CN113789347B (zh) * 2021-09-23 2022-07-22 徐州医科大学 Fgl1/caix双靶点疫苗在治疗肾癌和肾癌肺转移中的应用
CN114480298A (zh) * 2022-04-14 2022-05-13 迈杰转化医学研究(苏州)有限公司 一株分泌抗tigit单克隆抗体的杂交瘤细胞株及其应用
CN114480298B (zh) * 2022-04-14 2022-06-24 迈杰转化医学研究(苏州)有限公司 一株分泌抗tigit单克隆抗体的杂交瘤细胞株及其应用

Also Published As

Publication number Publication date
CN111542546B (zh) 2022-08-16
US20200347131A1 (en) 2020-11-05
US11655295B2 (en) 2023-05-23
WO2019141092A1 (zh) 2019-07-25

Similar Documents

Publication Publication Date Title
CN111542546B (zh) 抗lag-3抗体及其用途
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
RU2693661C2 (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
RU2725811C1 (ru) Антитела против 4-1bb человека и их применение
US20230192840A1 (en) Antibody and use thereof
WO2020098734A1 (zh) 抗tigit抗体及其用途
CN110950953B (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
US20190321466A1 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
CA3092456A1 (en) Anti-tigit antibody and use thereof
CN110734493B (zh) 抗pd-1抗体及其用途
CN111454358A (zh) 一种嵌合抗原受体及其应用
US20230203178A1 (en) Chimeric antigen receptor car or car construct targeting bcma and cd19 and application thereof
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
TW202016143A (zh) 全人源的抗ｌａｇ－３抗體及其應用
CN115812081A (zh) 抗ctla-4抗体及其用途
WO2022171080A1 (zh) 抗cd112r抗体及其用途
CN113698492A (zh) 人间皮素嵌合抗原受体及其用途
JP2022550243A (ja) 抗ｐｄ－１抗体及びその使用
CN115873115A (zh) 一种抗4-1bb单克隆抗体在肿瘤免疫治疗上的应用
CN115521378B (zh) Pd-l1抗体及其用途
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
EP4375300A1 (en) Pharmaceutical composition and use
WO2023173393A1 (zh) 结合b7-h3的抗体及其用途
TW202413430A (zh) 抗ｃｄ３７和ｃｄ３的雙特異性抗體
TW202235436A (zh) Ｓｉｇｌｅｃ－１５結合蛋白的製備及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034214

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210729

Address after: NO.666, Section 2, Xinhua Avenue, cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province

Applicant after: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL Co.,Ltd.

Address before: NO.666, Section 2, Xinhua Avenue, cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province

Applicant before: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL Co.,Ltd.

Applicant before: Anyuan Pharmaceutical Technology (Shanghai) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant